United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Breakthrough trial: Oncolytics Biotech’s pelareorep combo doubles response rate in advanced anal cancer Find out how Oncolytics Biotech’s breakthrough trial doubled response rates in advanced anal cancer and set up a 2026 FDA path. bySoujanya RaviOctober 28, 2025